Attenuated dengue virus vaccine containing adaptive mutation from mrc-5 cells

Abstract

The present invention relates to an attenuated dengue virus vaccine. In present invention, target mutagenesis at Glu345Lys was constructed in two infectious cDNA clones of a recombinant version of wild type virus DEN-4 2A and its derived 3′ NCR deletion mutant vaccine candidate virus DEN-4 2AΔ30. Using PCR-mediated site-directed mutagenesis method, the infectious cDNA clone-derived Glu345-Lys mutants of DEN-4 2A and DEN-4 2AΔ30 were passaged in Vero cells and MRC-5 cells for five consecutive times. The results shows that single point mutation E-Glu345Lys of DEN-4 2A and DEN-4 2AΔ30 were found stably existed when passaged in MRC-5 cells, which means mutagenesis at Glu345Lys of DEN-4 2A and DEN-4 2AΔ30 are both suitable to be probagated in MRC-5 cell for producing virulence attenuated dengue virus vaccine.

Dependencies are inferred from the claim text.